Back to Search Start Over

Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis

Authors :
Elisabetta Poluzzi
Bernard Bégaud
Francesco Salvo
Julie Mouchet
Ippazio Cosimo Antonazzo
Fabrizio De Ponti
Emanuel Raschi
Bordeaux population health (BPH)
Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Mouchet, Julie
Salvo, Francesco
Raschi, Emanuel
Poluzzi, Elisabetta
Antonazzo, Ippazio Cosimo
De Ponti, Fabrizio
Bégaud, Bernard
Mouchet, J
Salvo, F
Raschi, E
Poluzzi, E
Antonazzo, I
De Ponti, F
Begaud, B
Source :
Pharmacological Research, Pharmacological Research, Elsevier, 2018, 132, pp.108-118. ⟨10.1016/j.phrs.2018.04.007⟩
Publication Year :
2018
Publisher :
HAL CCSD, 2018.

Abstract

BACKGROUND: Approved in 2006, human papillomavirus (HPV) vaccines were initially targeted for girls aged 9-14 years. Although the safety of these vaccines has been monitored through post-licensure surveillance programmes, cases of neurological events have been reported worldwide. PURPOSE: The present study aimed to assess the risk of developing demyelination after HPV immunization by meta-analysing risk estimates from pharmacoepidemiologic studies. DATA SOURCES: A systematic review was conducted in Medline, Embase, ISI Web of Science and the Cochrane Library from inception to 10 May 2017, without language restriction. STUDY SELECTION: Only observational studies including a control group were retained. Study selection was performed by two independent reviewers with disagreements solved through discussion. DATA EXTRACTION: This meta-analysis was performed using a generic inverse variance random-effect model. Outcomes of interest included a broad category of central demyelination, multiple sclerosis (MS), optic neuritis (ON), and Guillain-Barre syndrome (GBS), each being considered independently. Heterogeneity was investigated; sensitivity and subgroup analyses were performed when necessary. In parallel, post-licensure safety studies were considered for a qualitative review. This study followed the PRISMA statement and the MOOSE reporting guideline. DATA SYNTHESIS: Of the 2863 references identified, 11 articles were selected for meta-analysis. No significant association emerged between HPV vaccination and central demyelination, the pooled odds ratio being 0.96 [95%CI 0.77-1.20], with a moderate but non-significant heterogeneity (I(2)=29%). Similar results were found for MS and ON. Sensitivity analyses did not alter our conclusions. Findings from qualitative review of 14 safety studies concluded in an absence of a relevant signal. LIMITATIONS: Owing to limited data on GBS, no meta-analysis was performed for this outcome. CONCLUSION: This study strongly supports the absence of association between HPV vaccines and central demyelination.

Details

Language :
English
ISSN :
10436618 and 10961186
Database :
OpenAIRE
Journal :
Pharmacological Research, Pharmacological Research, Elsevier, 2018, 132, pp.108-118. ⟨10.1016/j.phrs.2018.04.007⟩
Accession number :
edsair.doi.dedup.....21b2f199d84884121a3fb3f1b6f34bfd
Full Text :
https://doi.org/10.1016/j.phrs.2018.04.007⟩